Get the Stockscreener App
0.00
100.00%
-1.74
Lava Therapeutics Nv stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.74
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$45.77M
Revenue:
$4.99M
Net Income/Loss:
$-28.29M
P/E Ratio:
0.00
EPS:
-1.0528
Net Cash Flow:
$-36.20M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$1.825
52-Week Range:
$0.00
$2.00
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
0.00 | 45.77M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
XOMA Royalty completes acquisition of LAVA Therapeutics By Investing.com - Investing.com Nigeria
Lava Therapeutics shares delisted from Nasdaq following completion of acquisition - Investing.com Nigeria
Lava Therapeutics shares delisted from Nasdaq following completion of acquisition By Investing.com - Investing.com South Africa
XOMA Completes Acquisition of LAVA Therapeutics - TipRanks
Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V. - MarketScreener
XOMA Royalty Corporation Completes Acquisition of LAVA Therapeutics N.V. - Quiver Quantitative
XOMA Royalty (Nasdaq: XOMA) completes LAVA deal; investors get $1.04 plus CVR - Stock Titan
Will LAVA Therapeutics N.V. stock benefit from AI adoption2025 Big Picture & Weekly High Return Opportunities - newser.com
What makes LAVA Therapeutics N.V. (4PKB) stock appealing to growth investorsIPO Watch & High Return Stock Watch Alerts - newser.com
What analysts say about LAVA Therapeutics NV 4PKB stockRisk-Reward Ratio Analysis & Fast Profit Portfolio Plans - earlytimes.in
How LAVA Therapeutics N.V. (4PKB) stock expands through international markets2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
How LAVA Therapeutics N.V. (4PKB) stock trades in high volatilityChart Signals & Proven Capital Preservation Tips - newser.com
How LAVA Therapeutics N.V. stock performs during Fed tightening cyclesQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Will LAVA Therapeutics N.V. (4PKB) stock outperform small cap peersMarket Performance Report & Verified Stock Trade Ideas - newser.com
Will LAVA Therapeutics N.V. (4PKB) stock justify high valuationWeekly Profit Report & Expert Curated Trade Setup Alerts - newser.com
Why hedge funds are buying LAVA Therapeutics N.V. stockJuly 2025 Setups & Entry Point Confirmation Signals - newser.com
Advanced analytics toolkit walkthrough for LAVA Therapeutics N.V.Sell Signal & High Yield Stock Recommendations - newser.com
Will LAVA Therapeutics N.V. stock benefit from green energy trendsWall Street Watch & Expert Curated Trade Ideas - newser.com
Can LAVA Therapeutics N.V. (4PKB) stock expand revenue streamsWeekly Investment Report & Technical Confirmation Alerts - newser.com
How to track smart money flows in LAVA Therapeutics N.V.2025 Winners & Losers & Daily Profit Focused Screening - newser.com
Is LAVA Therapeutics N.V. showing signs of accumulationWall Street Watch & Reliable Intraday Trade Alerts - newser.com
How LAVA Therapeutics N.V. stock valuations compare to rivals2025 Trade Ideas & Technical Confirmation Trade Alerts - newser.com
Why LAVA Therapeutics N.V. (4PKB) stock stays on buy listsWeekly Trade Analysis & Safe Swing Trade Setups - newser.com
Published on: 2025-11-19 00:31:28 - newser.com
Analyzing LAVA Therapeutics N.V. with risk reward ratio chartsPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
Custom strategy builders for tracking LAVA Therapeutics N.V.July 2025 Levels & Weekly High Conviction Ideas - newser.com
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):